These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 3741725)

  • 1. Investigation of patients with abnormal response to warfarin.
    Bentley DP; Backhouse G; Hutchings A; Haddon RL; Spragg B; Routledge PA
    Br J Clin Pharmacol; 1986 Jul; 22(1):37-41. PubMed ID: 3741725
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Interaction of sulphinpyrazone with warfarin.
    Miners JO; Foenander T; Wanwimolruk S; Gallus AS; Birkett DJ
    Eur J Clin Pharmacol; 1982; 22(4):327-31. PubMed ID: 7106169
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Switching from rivaroxaban to warfarin: an open label pharmacodynamic study in healthy subjects.
    Moore KT; Byra W; Vaidyanathan S; Natarajan J; Ariyawansa J; Salih H; Turner KC
    Br J Clin Pharmacol; 2015 Jun; 79(6):907-17. PubMed ID: 25475601
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Role of desethylamiodarone in the anticoagulant effect of concurrent amiodarone and warfarin therapy.
    Naganuma M; Shiga T; Nishikata K; Tsuchiya T; Kasanuki H; Fujii E
    J Cardiovasc Pharmacol Ther; 2001 Oct; 6(4):363-7. PubMed ID: 11907638
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A flexible loading dose schedule for warfarin therapy.
    Fergusson RJ; Eade OE; Logie AW; Gaddie J
    Scott Med J; 1987 Dec; 32(6):169-71. PubMed ID: 3329767
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prothrombin levels maintained with meprobamate and warfarin. A controlled study.
    Gould L; Michael A; Fisch S; Gomprecht RF
    JAMA; 1972 Jun; 220(11):1460-2. PubMed ID: 4623950
    [No Abstract]   [Full Text] [Related]  

  • 7. Contribution of rivaroxaban to the international normalized ratio when switching to warfarin for anticoagulation as determined by simulation studies.
    Siegmund HU; Burghaus R; Kubitza D; Coboeken K
    Br J Clin Pharmacol; 2015 Jun; 79(6):959-66. PubMed ID: 25510952
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Effects of Teicoplanin on the PT-INR Controlled by Warfarin in Infection Patients].
    Nakano T; Nakamura T; Nakamura Y; Irie K; Sato K; Matsuo K; Imakyure O; Ogata K; Mishima K; Kamimura H
    Yakugaku Zasshi; 2017; 137(7):909-916. PubMed ID: 28674307
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Active Metabolite of Warfarin (3'-Hydroxywarfarin) and Correlation with INR, Warfarin and Drug Weekly Dosage in Patients under Oral Anticoagulant Therapy: A Pharmacogenetics Study.
    Gemmati D; Burini F; Talarico A; Fabbri M; Bertocco C; Vigliano M; Moratelli S; Cuneo A; Serino ML; Avato FM; Tisato V; Gaudio RM
    PLoS One; 2016; 11(9):e0162084. PubMed ID: 27606428
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Initiation of warfarin therapy in elderly medical inpatients: a safe and accurate regimen.
    Siguret V; Gouin I; Debray M; Perret-Guillaume C; Boddaert J; Mahé I; Donval V; Seux ML; Romain-Pilotaz M; Gisselbrecht M; Verny M; Pautas E
    Am J Med; 2005 Feb; 118(2):137-42. PubMed ID: 15694897
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The effect of rofecoxib on the pharmacodynamics and pharmcokinetics of warfarin.
    Schwartz JI; Bugianesi KJ; Ebel DL; De Smet M; Haesen R; Larson PJ; Ko A; Verbesselt R; Hunt TL; Lins R; Lens S; Porras AG; Dieck J; Keymeulen B; Gertz BJ
    Clin Pharmacol Ther; 2000 Dec; 68(6):626-36. PubMed ID: 11180023
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mechanism of warfarin potentiation by amiodarone: dose--and concentration--dependent inhibition of warfarin elimination.
    Almog S; Shafran N; Halkin H; Weiss P; Farfel Z; Martinowitz U; Bank H
    Eur J Clin Pharmacol; 1985; 28(3):257-61. PubMed ID: 4007030
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Kiiv, an in vivo parameter for predicting the magnitude of a drug interaction arising from competitive enzyme inhibition.
    Neal JM; Kunze KL; Levy RH; O'Reilly RA; Trager WF
    Drug Metab Dispos; 2003 Aug; 31(8):1043-8. PubMed ID: 12867493
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dose-dependent artificial prolongation of prothrombin time by interaction between daptomycin and test reagents in patients receiving warfarin: a prospective in vivo clinical study.
    Saito M; Hatakeyama S; Hashimoto H; Suzuki T; Jubishi D; Kaneko M; Kume Y; Yamamoto T; Suzuki H; Yotsuyanagi H
    Ann Clin Microbiol Antimicrob; 2017 Apr; 16(1):27. PubMed ID: 28399872
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Multiple doses of sitagliptin, a selective DPP-4 inhibitor, do not meaningfully alter pharmacokinetics and pharmacodynamics of warfarin.
    Wright DH; Herman GA; Maes A; Liu Q; Johnson-Levonas AO; Wagner JA
    J Clin Pharmacol; 2009 Oct; 49(10):1157-67. PubMed ID: 19783710
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of two cimetidine regimens on prothrombin time and warfarin pharmacokinetics during long-term warfarin therapy.
    Sax MJ; Randolph WC; Peace KE; Chretien S; Frank WO; Braverman AJ; Gray DR; McCree LC; Wyle F; Jackson BJ
    Clin Pharm; 1987 Jun; 6(6):492-5. PubMed ID: 3690995
    [No Abstract]   [Full Text] [Related]  

  • 17. Vitamin K-independent warfarin resistance after concurrent administration of warfarin and continuous enteral nutrition.
    Dickerson RN; Garmon WM; Kuhl DA; Minard G; Brown RO
    Pharmacotherapy; 2008 Mar; 28(3):308-13. PubMed ID: 18294110
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The effect of the plasma levels of proteins C and S on the prediction of warfarin maintenance dose requirements.
    Lubetsky A; Seligsohn U; Ezra D; Halkin H
    Clin Pharmacol Ther; 1992 Jul; 52(1):42-9. PubMed ID: 1385564
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Flexible induction dose regimen for warfarin and prediction of maintenance dose.
    Fennerty A; Dolben J; Thomas P; Backhouse G; Bentley DP; Campbell IA; Routledge PA
    Br Med J (Clin Res Ed); 1984 Apr; 288(6426):1268-70. PubMed ID: 6424820
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Serum protein binding as a determinant of warfarin body clearance and anticoagulant effect.
    Yacobi A; Udall JA; Levy G
    Clin Pharmacol Ther; 1976 May; 19(5 Pt 1):552-8. PubMed ID: 1277711
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.